Free Trial
NYSE:HAE

Haemonetics Q4 2025 Earnings Report

Haemonetics logo
$63.94 +0.95 (+1.51%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$63.90 -0.04 (-0.06%)
As of 05/2/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haemonetics EPS Results

Actual EPS
N/A
Consensus EPS
$1.22
Beat/Miss
N/A
One Year Ago EPS
N/A

Haemonetics Revenue Results

Actual Revenue
N/A
Expected Revenue
$329.38 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Haemonetics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Haemonetics Earnings Headlines

Haemonetics (HAE) Projected to Post Earnings on Thursday
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Haemonetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Haemonetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Haemonetics and other key companies, straight to your email.

About Haemonetics

Haemonetics (NYSE:HAE), a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

View Haemonetics Profile

More Earnings Resources from MarketBeat